SRX3207

Names

[ CAS No. ]:
2254693-15-5

[ Name ]:
SRX3207

Biological Activity

[Description]:

SRX3207 is an orally active and first-in-class dual Syk/PI3K inhibitor. SRX3207 possesses anti-tumor activity[1].

[Related Catalog]:

Research Areas >> Cancer

Signaling Pathways >> PI3K/Akt/mTOR >> PI3K

Signaling Pathways >> Protein Tyrosine Kinase/RTK >> Syk

[In Vitro]

SRX3207 (10 μmol/L) is able to block p-AKT at concentration[1]. SRX3207 has sufficient solubility in water (43 μmol/L)[1].

[In Vivo]

SRX3207 (10 mg/kg, orally) increases antitumor immune response[1]. Animal Model: LLC or B16 or B16-OVA or CT26 (1 × 105) cells were injected subcutaneously into syngeneic mice[1]. Dosage: 10 mg/kg. Administration: Orally, starting from day 10 when tumors reached 100 mm3 until tumors were harvested on day 21. Result: Blocked phosphorylation of Syk at 348 site and Y525/526 site. Blocked immunosuppressive MΦ polarization. Blocked tumor growth and increased survival effectively.

[References]

[1]. Shweta Joshi, et al. Macrophage Syk–PI3Kγ Inhibits Antitumor Immunity: SRX3207, a Novel Dual Syk–PI3K Inhibitory Chemotype Relieves Tumor Immunosuppression. Molecular Cancer Therapeutics. 2020.

Chemical & Physical Properties

[ Molecular Formula ]:
C₂₉H₂₉N₇O₃S

[ Molecular Weight ]:
555.65

[ Storage condition ]:
-20°C

SRX3207

Names

Biological Activity

Chemical & Physical Properties

Related Compounds